Evidence map›Paper›PMID 39572448›Full record

ArticleEuropean radiology2025

Relationship between [

Hongyan Yin, Rongkui Luo, Jing Lv, Wujian Mao, Hongcheng Shi

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Imaging-based stratification of Claudin 18.2-positive gastric adenocarcinoma usingEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hongyan YinDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Rongkui LuoDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jing LvDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Wujian MaoDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Hongcheng ShiDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China. shi.hongcheng@zs-hospital.sh.cn.ORCID http://orcid.org/0000-0003-4813-4262

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimGiven that claudin 18.2 (CLDN18.2) is a cell surface protein specifically expressed by gastric cancer cells, anti-CLDN18.2 antibodies have demonstrated significant antitumor effects in patients with advanced gastric adenocarcinoma. The correlation of [

methodsA retrospective analysis of [

resultsCLDN18.2-negative tumors showed a higher median SUV

conclusionRelatively reduced [ KEY POINTS: Question The study resolves the clinical issue of determining the correlation between [

Indexed as

AdenocarcinomaClaudinsFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyStomach NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRadiopharmaceuticalsRetrospective StudiesClaudinsCLDN18 protein, humanFluorodeoxyglucose F18RadiopharmaceuticalsClaudin 18.2Gastric cancerPET/CTSUVmax

Identifiers

PMID39572448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.